FDA proposes permanent 503B ban on compounded semaglutide and tirzepatide

The FDA has proposed permanently barring semaglutide, tirzepatide and liraglutide from bulk production at large compounding facilities, and it extended the deadline for public comments on that plan from June 30 to July 30, 2026 ^[1]. The proposal was issued in May 2026 and is not final ^[1].

What the proposal would change

Federal law separates two kinds of compounding. A 503A pharmacy is licensed by a state and mixes a medication for one patient with one prescription ^[1][2]. A 503B outsourcing facility is registered with the FDA, follows current Good Manufacturing Practice standards, and can produce large batches without patient-specific prescriptions, then ship them at scale ^[2]. That large-batch model is what made high-volume compounded semaglutide subscriptions possible ^[1].

The May 2026 proposal would remove semaglutide, tirzepatide and liraglutide from the 503B bulk drug substances list ^[1]. A separate FDA clarification in April 2026 said compounders cannot sell what amounts to a copy of a commercially available drug in the same or similar strength ^[1][2]. A compounding pharmacy, Nationwide Compounding, wrote on June 17, 2026 that the proposed 503B exclusion does not close the 503A pathway, which remains available for documented, patient-specific needs such as an allergy to an inactive ingredient in Ozempic, Wegovy or Rybelsus, or a need for a dosage form that is not commercially sold ^[2]. That account states that cost alone is not a recognized basis for 503A compounding ^[2].

A July 13, 2026 article from Med Matrix, a clinic that uses FDA-approved semaglutide and tirzepatide, reported that the comment period was extended after industry groups asked for 60 additional days and the FDA granted 30 ^[1].

Enforcement before the proposal

Both accounts describe a run of enforcement actions. Med Matrix lists about 80 warning letters to telehealth companies in September 2025, a February 2026 FDA Commissioner announcement on targeted enforcement, roughly 30 more letters in March 2026, the April 2026 copy clarification, and a wave of 25 warning letters in the week of June 15, 2026 ^[1]. Nationwide Compounding describes more than 50 warning letters in March 2026 alone, which it calls the largest such wave against GLP-1 compounders, and cites a February 20, 2026 warning letter to Join Josie over false or misleading claims ^[2]. The two sources disagree on the March 2026 count.

On safety, Med Matrix reports more than 455 adverse event reports tied to compounded semaglutide and more than 320 tied to compounded tirzepatide as of early 2025 ^[1]. Nationwide Compounding cites 520 reports for compounded semaglutide as of April 30, 2025 ^[2]. The figures use different dates and scopes. Nationwide Compounding says one of the most frequently reported problems is patients injecting 5 to 20 times the intended dose because of confusion between units and mg/mL concentrations on multidose vials ^[2]. Med Matrix says many reports trace to dosing errors from multidose vials ^[1]. Compounded drugs are not reviewed by the FDA for safety or effectiveness before they are sold ^[1].

Why it matters for patients

Compounded semaglutide remained legal to buy as of July 2026, and nothing changes on July 30 — that date is the comment deadline, not a shutdown date ^[1]. What would change if the rule is finalized is supply: 503B facilities would have to stop bulk production of the three drugs, and the pipeline feeding many compounded programs would shrink ^[1]. Nationwide Compounding typically priced compounded semaglutide at $150 to $400 per month and listed brand-name Ozempic or Wegovy at $935 to $1,349 per month without insurance ^[2], the gap that drove demand. Med Matrix says that gap has narrowed, citing an oral Wegovy approved December 22, 2025 at $149 a month without insurance ^[1]. Moving between a compounded vial and an FDA-approved product is a clinical decision, and doses do not always map one-to-one ^[1]. Whether a specific insurer covers a branded product is not addressed in either account.

What happens next

The comment period closes July 30, 2026 ^[1]. The FDA then reviews the comments and decides when to finalize the rule; no date for that decision has been published ^[1]. Nationwide Compounding says industry analysts widely expect finalization in the third quarter of 2026 ^[2]. Once final, 503B facilities would have to stop bulk production of semaglutide, tirzepatide and liraglutide ^[1].